65,437 trials
Ornithine Transcarbamylase (OTC) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and TEAEs Leading to Discontinuation…
HIV/AIDS
Primary: Retention in Care - Yes Responses — 19; 23 Participants
Electronic Cigarettes
Primary: Plasma Nicotine Concentration — 12.32; -0.22; 7.09; 5.85 ng/ml
Hiv
Primary: Timely Viral Suppression (TVS) — 254; 261; 277; 168 Participants
Tinnitus, Subjective
Primary: Audiometry - Pure Tone Average Done Over 1000, 2000 and 4000 Hertz (HZ) — -0.3; 0.71; -0.8; 0.3 decibels
Vitamin D Deficiency · Vitamin D Insufficiency
Primary: Serum 25-hydroxyvitamin D — 25.4 ng/nl
Dietary Habits · Health Behavior · Eating Behavior
Primary: Estimated Change in Child Fruit & Vegetable Self-efficacy — 0.47; 0.24 score on a scale — p=0.017
Malignant Ovarian Clear Cell Tumor · Recurrent Ovarian Carcinoma
Primary: Complete or Partial Objective Tumor Response — 3 Participants
TBI (Traumatic Brain Injury)
Primary: Percent Change in Trail Making Test Part B Time to Completion — -25.6 percent change in time
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Visual Acuity
Primary: Overall Comfort (Phase I) — 45; 32; 20; 23 Number of responses
Metabolic Syndrome · Obesity · Dyslipidemias
Primary: Dyslipidemia Measures — 30; 32 mg/dL
SARS-CoV-2 Infection · COVID-19
Primary: Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study…
Sleep Fragmentation · Poor Quality Sleep · Nocturia
Primary: Change in Nocturnal Polyuria Index — 41.7; 41.7; 34.5; 37.8 percentage of urine volume — p=0.3
Dental Caries
Primary: Antimicrobial Activity of C16G2 — -0.2; -0.04; 0.005; 0.15 CFU/mL